Gene · 488
NIH grants2,537
NIH grants whose papers are about the gene, through NIH's grant-paper links.
21 to 40 of 2,537
Download this page as JSON| Grant | Title | ATP2A2 papers | Newest fiscal year |
|---|---|---|---|
| P30DK056341 | Washington University Nutrition Obesity Research Center | 3 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 3 | 2025 |
| R01AA028527 | Alcohol-induced cardiac injury and repair in human induced pluripotent stem cell model | 3 | 2025 |
| R01DK097441 | Molecular mechanisms of UCP1-independent pathways in metabolic health | 3 | 2025 |
| R01HL113006 | Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling | 3 | 2025 |
| R01HL131017 | Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytes | 3 | 2025 |
| R01HL139613 | Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension | 3 | 2025 |
| R01HL142282 | CaMKII activation and regulation in adult cardiac myocytes | 3 | 2025 |
| R01HL143816 | Membrane Micropeptides and Calcium Pump Allostery | 3 | 2025 |
| T32AR007612 | Minnesota Muscle Training Program | 3 | 2025 |
| T32HL007381 | Cardiovascular Sciences Training Grant | 3 | 2025 |
| T32HL094274 | Training in Myocardial Biology at Stanford | 3 | 2025 |
| ZIAAG000263 | EPAC, PKC and CaMKII regulate local Ca2+ releases and cardiac pacemaker firing | 3 | 2025 |
| K08HL155852 | Targeting Pannexin 1 as a Novel Mechanism for Arrhythmia and Fibrosis in Duchenne Cardiomyopathy | 2 | 2025 |
| K12GM119955 | The Minnesota IRACDA Program | 2 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P01CA125066 | Discovery of Anticancer Agents of Diverse Natural Origin | 2 | 2025 |
| P01HL134599 | Morphogenesis and growth of the ventricular wall in development and disease | 2 | 2025 |
| P20GM121176 | Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2. | 2 | 2025 |
| P30AG021332 | Wake Forest Claude D. Pepper OAIC - Renewal | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/488/grants?page=2